Skip to main content
OpenTrials

Clinical trial condition

Gastroesophageal Junction

Explore clinical trials studying Gastroesophageal Junction. Study availability and eligibility vary by location and protocol.

7 public trials 4 recruiting studies
Refine in advanced search Browse all conditions

Gastroesophageal Junction trial results

Recruiting

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

NCT06445972

Conditions
Digestive System Diseases, Digestive System Neoplasms, Esophageal Cancer, +10 more
Locations
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 8927) Tucson, Arizona, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 8905) Los Angeles, California, United States
  • Norton Cancer Institute - Downtown ( Site 8900) Louisville, Kentucky, United States
  • The Cancer and Hematology Centers ( Site 8912) Grand Rapids, Michigan, United States
View all 47 locations
View Trial Details
Recruiting

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

NCT07546812

Conditions
Adenocarcinoma Of Esophagus, Esophageal Adenocarcinoma, Gastric Adenocarcinoma, +2 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Chris O'Brien Lifehouse Camperdown, New South Wales, Australia
  • Royal Brisbane and Women's Hospital Herston, Queensland, Australia
  • Hollywood Private Hospital Nedlands, Western Australia, Australia
View Trial Details
Recruiting

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

NCT07217704

Conditions
Digestive System Diseases, Digestive System Neoplasms, Esophageal Cancer, +11 more
Locations
  • Helios CR Inc./RadNet Cerritos, California, United States
  • City of Hope National Cancer Center Duarte, California, United States
  • Hoag Memorial Hospital Irvine, California, United States
  • UCLA Los Angeles, California, United States
View all 15 locations
View Trial Details
Recruiting

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

NCT06469944

Conditions
Digestive System Diseases, Digestive System Neoplasms, Esophageal Cancer, +10 more
Locations
  • University of Arizona Cancer Center-University of Arizona Cancer Center ( Site 6927) Tucson, Arizona, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 6905) Los Angeles, California, United States
  • Norton Hospital-Norton Cancer Institute - Downtown ( Site 6900) Louisville, Kentucky, United States
  • The Cancer and Hematology Centers ( Site 6912) Grand Rapids, Michigan, United States
View all 51 locations
View Trial Details
Active, Not Recruiting

MAGE-A4ᶜ¹º³²T for Multi-Tumor

NCT03132922

Conditions
Adenocarcinoma, Adnexal Diseases, Bronchial Neoplasms, +67 more
Locations
  • University of Miami Miami, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Washington University St Louis, Missouri, United States
View Trial Details

Related conditions